WallStSmart
VYGR

Voyager Therapeutics Inc

NASDAQ: VYGR · HEALTHCARE · BIOTECHNOLOGY

$3.73
+2.47% today

Updated 2026-04-30

Market cap
$224.69M
P/E ratio
P/S ratio
5.57x
EPS (TTM)
$-2.04
Dividend yield
52W range
$3 – $6
Volume
0.7M

Voyager Therapeutics Inc (VYGR) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item2013201420152016201720182019202020212022202320242025
Revenue$0.00$17.33M$14.22M$10.13M$7.62M$104.39M$171.13M$37.41M$40.91M$250.01M$80.00M$40.37M
Revenue growth (YoY)-18.0%-28.7%-24.8%+1270.1%+63.9%-78.1%+9.3%+511.2%-68.0%-49.5%
Cost of revenue$4.63M$8.90M$27.68M$42.25M$62.26M$64.91M$119.73M$108.75M$73.79M$6.19M$92.17M$4.73M$4.06M
Gross profit$-4.63M$-8.90M$17.33M$14.22M$10.13M$7.62M$104.39M$62.38M$37.41M$40.91M$157.84M$80.00M$40.37M
Gross margin100.0%100.0%100.0%100.0%100.0%36.4%100.0%100.0%63.1%100.0%100.0%
R&D$4.63M$8.90M$27.68M$42.25M$62.26M$64.91M$119.73M$108.75M$73.79M$60.76M$92.17M$127.37M$134.67M
SG&A$2.90M$5.47M$9.91M$13.27M$19.74M$33.81M$36.34M$34.99M$37.25M$30.98M$35.82M$35.92M$37.54M
Operating income$-7.53M$-14.37M$-20.25M$-41.30M$-71.86M$-91.09M$-51.68M$27.38M$-73.62M$-50.84M$122.01M$-83.29M$-131.84M
Operating margin-116.8%-290.4%-709.1%-1195.6%-49.5%16.0%-196.8%-124.3%48.8%-104.1%-326.6%
EBITDA$-134000.00$-14.18M$-19.65M$-40.69M$-70.27M$-88.98M$-48.91M$31.20M$-68.45M$-44.65M$126.45M$-78.56M$-127.78M
EBITDA margin-113.4%-286.1%-693.3%-1167.8%-46.9%18.2%-183.0%-109.1%50.6%-98.2%-316.5%
EBIT$-7.67M$-14.37M$-20.25M$-41.30M$-71.86M$-91.09M$-51.68M$27.38M$-73.62M$-50.84M$122.01M$-83.29M$-131.84M
Interest expense$0.00$332000.00$976000.00$0.00$0.00$0.00$0.00$390000.00$1.79M
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-7.67M$-16.32M$-29.67M$-40.19M$-70.70M$-88.29M$-40.83M$36.74M$-66.03M$-46.41M$132.33M$-65.00M$-119.72M
Net income growth (YoY)-112.8%-81.8%-35.5%-75.9%-24.9%+53.8%+190.0%-279.7%+29.7%+385.1%-149.1%-84.2%
Profit margin-171.2%-282.7%-697.6%-1158.8%-39.1%21.5%-176.5%-113.4%52.9%-81.3%-296.5%